Osteopontin Enhances the Cell Proliferation Induced by the Epidermal Growth Factor in Human Prostate Cancer Cells

Prostate

Volumn 59, Issue 2, 2004, Pages 157-166

  Angelucci, Adriano ^a,b   Festuccia, Claudio ^a   Gravina, Giovanni Luca ^b   Muzi, Paola ^a   Bonghi, Loriana ^a   Vicentini, Carlo ^b   Bologna, Mauro ^a,b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Bone metastasis; EGFR phosphorylation; Integrin 1; LNCaP; Prostate carcinoma

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BETA1 INTEGRIN; CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; OSTEOPONTIN; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RECOMBINANT EPIDERMAL GROWTH FACTOR;

ARTICLE; CELL CLONING; CELL MEMBRANE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; DILUTION; DISEASE COURSE; DISEASE PREDISPOSITION; EXTRACELLULAR MATRIX; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; STEROID ANALYSIS; TUMOR GROWTH;

BONE NEOPLASMS; CELL ADHESION; CELL DIVISION; CYTOKINES; DISEASE PROGRESSION; EPIDERMAL GROWTH FACTOR; HUMANS; MALE; OSTEOPONTIN; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIALOGLYCOPROTEINS; STROMAL CELLS;

EID: 1842631409     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20008     Document Type: Article

References (34)

1. Linehan WM, Long JP, Steeg PS, Gnarra JR. Metastatic models and molecular genetics of prostate cancer. J Natl Cancer Inst 1992;84:914-915.
2. Koeneman KS, Yeung F, Chung WK. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39:246-261.
3. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW. Osteopontin: Possible role in prostate cancer progression. Clin Cancer Res 1999;5:2271-2277.
4. Angelucci A, Festuccia C, D'Andrea G, Teti A, Bologna M. Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators. Biol Chem 2002;383:229-234.
5. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994;145:610-623.
6. Craig AM, Bowden GT, Chambers AF, Spearman MA, Greenberg AH, Wright JA, McLeod M, Denhardt DT. Secreted phosphoprotein mRNA is induced during multi-stage carcino-genesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J Cancer 1990;46:133-137.
7. Oates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 1997;17: 1-15.
8. Dedhar S, Saulnier R, Nagle R, Overall CM. Specific alterations in the expression of alpha 3 beta 1 and alpha 6 beta 4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane. Clin Exp Metastasis 1993;11:391-400.
9. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 2000;78:465-475.
10. Schwartz MA, Baron V. Interactions between mitogenic stimuli, or, a thousand and one connections. Curr Opin Cell Biol 1999;11:197-202.
11. Miyamoto S, Teramoto H, Gutkind JS, Yamada KM. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: Roles of integrin aggregation and occupancy of receptors. J Cell Biol 1996;135:1633-1642.
12. Jones PL, Crack J, Rabinovitch MJ. Regulation tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth. Cell Biol 1997;139: 279-293.
13. Rodeck U, Jost M, Kari C, Shih DT, Lavker RM, Ewert DL, Jensen PJ. EGF-R dependent regulation of keratinocyte survival. J Cell Sci 1997;110:113-121.
14. Moro L, Venturino M, Bozzo C, Silengo L, Altruda F, Beguinot L, Tarone G, Defilippi P. Integrins induce activation of EGF receptor: Role in MAP kinase induction and adhesion-dependent cell survival. EMBO J 1998;17:6622-6632.
15. Kuwada SK, Li X. Integrin alpha5/beta1 mediates fibronectin-dependent epithelial cell proliferation through epidermal growth factor receptor activation. Mol Biol Cell 2000;11:2485-2496.
16. Kim HG, Kassis J, Souto JC, Turner T, Wells A. EGF receptor signalling in prostate morphogenesis and tumorigenesis. Histol Histopathol 1999;14:1175-1182.
17. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-3444.
18. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-212.
19. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P, Niklinski WT, Myers CE, Trepel JB. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 1994;91:5330-5334.
20. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis. Prostate 2000;44:91-103.
21. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 2002;52:20-33.
22. Gleave ME, Hsieh JT, von Eschenbach AC, Chung LW. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: Implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 1992; 147:1151-1159.
23. Festuccia C, Giunciuglio D, Guerra F, Villanova I, Angelucci A, Manduca P, Teti A, Albini A, Bologna M. Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion. Oncol Res 1999;11:17-31.
24. Knudsen BS, Silverstein RL, Leung LL, Harpel PC, Nachman RL. Binding of plasminogen to extracellular matrix. J Biol Chem 1986;261:10765-10771.
25. Bayless KJ, Davis GE, Meininger GA. Isolation and biological properties of osteopontin from bovine milk. Protein Expr Purif 1997;9:309-314.
26. Tozawa K, Yamada Y, Kawai N, Okamura T, Ueda K, Kohri K. Osteopontin expression in prostate cancer and benign prostatic hyperplasia. Urol Int 1999;62:155-158.
27. Carson JP, Kulik G, Weber MJ. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B. Cancer Res 1999;59:1449-1453.
28. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
29. Yamada KM, Miyamoto S. Integrin transmembrane signaling and cytoskeletal control. Curr Opin Cell Biol 1995;7:681-689.
30. Feng B, Rollo EE, Denhardt DT. Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: Evidence from cell lines down-regulated for OPN expression by a targeted ribozyme. Clin Exp Metastasis 1995;13:453-462.
31. Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 1996;13:97-104.
32. Liu AY, Corey E, Bladou F, Lange PH, Vessella RL. Prostatic cell lineage markers: Emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer 1996;65:85-89.
33. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 2001;280:460-465.
34. Jones HE, Barrow D, Dutkowski CM, Goddard L, Smith C, Harper ME, Nicholson RI. Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: Identification of divergent growth regulatory pathways. Prostate 2001; 49:38-47.